|
|
| Isotechnika makes executive changes |
| Isotechnika buoyed by deal with Vifor for voclosporin in lupus |
| Isotechnika Has Path Forward for Pivotal Trial |
| Isotechnika Partner Nears End of Patient Recruitment |
| Isotechnika Receives Positive Scientific Advice in Europe for voclosporin |
| Pharma Watch: 3SBio, Isotechnika Partner on Voclosporin |
| Isotechnika Lands China Deal |
| Isotechnika Pharma Signs $6M Commercialization Agreement for Transplant Organ Rejection Drug with 3S |
| Isotechnika Has a Powerhouse Franchise in Voclosporin |
| Paladin to Pay Isotechnika up to $2 Million for Diagnostic Line Profits |
| Isotechnika strikes strategic drug collaboration and financing deal with Paladin Labs |
| Edmonton business news: Brick, Churchill, Isotechnika |
| Paladin in joint venture for new psoriasis treatment |
| Paladin and Isotechnika Combine Forces to Advance Latter's Immunosuppressant |
| Isotechnika Nabs $11M in Voclosporin Pact |
| Isotechnika Reports Positive Phase 2b Trial of Voclosporin Kidney-Transplant Drug |
| Drug Wins Fast-Track Status |
| Isotechnika Drug Use Extended |
| Isotechnika Trial Wrapping Up |
| Isotechnika Drops Loan Facility |
|
|
|
|
|
|
|